SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis (EDKA) in Patients With Underlying Risk Factors

Abstract

Keywords

Sodium-Glucose Transporter 2 (SGLT2) inhibitors drug safety endocrinology diabetes patient education

Get full access to this article

View all access options for this article.

References

Peters

Buschur

Buse

Cohan

Diner

Hirsch

IB.

Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693. doi:10.2337/dc15-0843

Musso

Saba

Cassader

Gambino

Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020;371:m4147. doi:10.1136/bmj.m4147

Goldenberg

Berard

Cheng

AYY

, et al SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654-2664.e1. doi:10.1016/j.clinthera.2016.11.002

Ata

Yousaf

Khan

, et al SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021;11(1):10293. doi:10.1038/s41598-021-89752-w

Yang

Liu

Zhang

, et al Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1145587. doi:10.3389/fphar.2023.1145587

Bamgboye

Oni

Collier

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. 2021;77:651-657. doi:10.1007/s00228-020-03051-3

Naranjo

Busto

Sellers

, et al A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154

Watson

Dhaliwal

Robertshaw

, et al Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023;81(5):564-574. doi:10.1053/j.ajkd.2022.10.012